- Home
- PNI vs BEAT Comparison
PNI vs BEAT Comparison
Compare PNI & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNI
- BEAT
- Stock Information
- Founded
- PNI 2002
- BEAT 2015
- Country
- PNI United States
- BEAT United States
- Employees
- PNI N/A
- BEAT N/A
- Industry
- PNI Trusts Except Educational Religious and Charitable
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- PNI Finance
- BEAT Technology
- Exchange
- PNI Nasdaq
- BEAT Nasdaq
- Market Cap
- PNI 79.0M
- BEAT 74.1M
- IPO Year
- PNI N/A
- BEAT 2021
- Fundamental
- Price
- PNI $7.15
- BEAT $2.14
- Analyst Decision
- PNI
- BEAT Buy
- Analyst Count
- PNI 0
- BEAT 1
- Target Price
- PNI N/A
- BEAT $8.00
- AVG Volume (30 Days)
- PNI 26.4K
- BEAT 117.1K
- Earning Date
- PNI 01-01-0001
- BEAT 11-07-2024
- Dividend Yield
- PNI 4.76%
- BEAT N/A
- EPS Growth
- PNI N/A
- BEAT N/A
- EPS
- PNI N/A
- BEAT N/A
- Revenue
- PNI N/A
- BEAT N/A
- Revenue This Year
- PNI N/A
- BEAT N/A
- Revenue Next Year
- PNI N/A
- BEAT N/A
- P/E Ratio
- PNI N/A
- BEAT N/A
- Revenue Growth
- PNI N/A
- BEAT N/A
- 52 Week Low
- PNI $6.03
- BEAT $1.35
- 52 Week High
- PNI $7.89
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- PNI 43.59
- BEAT 39.59
- Support Level
- PNI $6.96
- BEAT $2.00
- Resistance Level
- PNI $7.27
- BEAT $2.30
- Average True Range (ATR)
- PNI 0.06
- BEAT 0.16
- MACD
- PNI 0.00
- BEAT -0.00
- Stochastic Oscillator
- PNI 61.29
- BEAT 35.00
About PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.